About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Dalpiciclib in HR+/HER2- ABC

NCT06301438·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Wenjin Yin
CONTACT
86(21)68385569 [email protected]

Lead

RenJi Hospital

Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Histologically confirmed advanced breast cancer
Hormone receptor-positive and human epidermal growth factor receptor 2-negative
ECOG 0-1

You may not be if

Pregnant or breastfeeding
History of immunodeficiency

The record

StatusRecruiting

PhaseNo phase

Taking part103

StartedMay 2024

UpdatedFeb 3, 2026

Conditions

Advanced Breast Cancer

Where1

Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, China

Clareo Health | Dalpiciclib in HR+/HER2- ABC